The use of ovarian function suppression (OFS) for the treatment of breast cancer in pre-menopausal women is low and little is known about medical oncologist' attitudes toward current guidelines pertaining to the use of OFS.
This purpose of this study was to explore breast medical oncologists' perceptions and use of gonadotropin-releasing hormone agonists as OFS for treatment of early-stage breast cancer.
